Low-dose Venetoclax and Azacitidine as Front-line Therapy in Newly Diagnosed AML - Trial NCT05048615
Access comprehensive clinical trial information for NCT05048615 through Pure Global AI's free database. This Phase 2 trial is sponsored by Hospital Universitario Dr. Jose E. Gonzalez and is currently Recruiting. The study focuses on AML. Target enrollment is 15 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Hospital Universitario Dr. Jose E. Gonzalez
Timeline & Enrollment
Phase 2
Jul 26, 2021
Jul 01, 2022
Primary Outcome
Feasibility will be address by obtaining the proportion of patients who need hospitalization,Safety will be defined by the number of patients deceased before 14 days of initiating treatment
Summary
Venetoclax plus azacitidine are effective in treating newly diagnosed AML in patients who
 cannot recieve intensive chemotherapy. However there is no clinical data rewarding the
 efficacy and safety of low-dose venetoclax and azacitidine as first-line therapy.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT05048615
Non-Device Trial